Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
2,023
Total Claims
$1.9M
Drug Cost
346
Beneficiaries
$5,523
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+291%
Cost per patient vs peers
$5,523 vs $1,411 avg
+671%
Brand preference vs peers
82.0% vs 10.6% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
Brand vs Generic
Brand: 1,432 claims · $1.9M
Generic: 314 claims · $8,185
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 224 | $399K |
| Insulin Glargine,hum.Rec.Anlog | 236 | $194K |
| Insulin Lispro | 129 | $176K |
| Semaglutide | 86 | $141K |
| Insulin Aspart | 85 | $135K |
| Empagliflozin | 107 | $122K |
| Liraglutide | 45 | $106K |
| Insulin Glargine,hum.Rec.Anlog | 73 | $63K |
| Insulin Lispro | 50 | $56K |
| Insulin Detemir | 39 | $54K |
| Tirzepatide | 34 | $54K |
| Sitagliptin Phosphate | 40 | $52K |
| Insulin Glargine,hum.Rec.Anlog | 40 | $51K |
| Insulin Lispro | 15 | $38K |
| Dapagliflozin Propanediol | 25 | $24K |
Prescribing Profile
Patient Profile
67
Avg Age
47%
Female
2.03
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About